Realizing the potential of agonistic antibody immunotherapy.

Mechanistic insights into agonistic antibodies could unlock their full potential in cancer and autoimmune therapies, with recent advances promising improved safety and efficacy.

• Why it matters: Despite their theoretical advantages, agonistic antibodies have shown limited clinical benefit, highlighting the need to better understand their mechanisms to enhance therapeutic outcomes.
• What they did: Researchers reviewed recent progress in understanding how agonistic antibodies trigger receptor signaling, focusing on tumor necrosis factor receptor superfamily proteins and immune receptor activation, involving over 100 studies.
• The result: These mechanistic insights are expected to expand the clinical applications of agonistic antibodies, enabling the development of more effective and safer immunotherapies for cancer and autoimmune diseases.